Oxaliplatino [Spanish] en es it fr

Oxaliplatino [Spanish] Brand names, Oxaliplatino [Spanish] Analogs

Oxaliplatino [Spanish] Brand Names Mixture

  • No information avaliable

Oxaliplatino [Spanish] Chemical_Formula


Oxaliplatino [Spanish] RX_link


Oxaliplatino [Spanish] fda sheet

Oxaliplatino_[Spanish] FDA

Oxaliplatino [Spanish] msds (material safety sheet)

Oxaliplatino_[Spanish] MSDS

Oxaliplatino [Spanish] Synthesis Reference

No information avaliable

Oxaliplatino [Spanish] Molecular Weight

395.27 g/mol

Oxaliplatino [Spanish] Melting Point

No information avaliable

Oxaliplatino [Spanish] H2O Solubility

No information avaliable

Oxaliplatino [Spanish] State


Oxaliplatino [Spanish] LogP

No information avaliable

Oxaliplatino [Spanish] Dosage Forms

No information avaliable

Oxaliplatino [Spanish] Indication

For the treatment of malignant neoplasm of colon, rectum, and ovary

Oxaliplatino [Spanish] Pharmacology

Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

Oxaliplatino [Spanish] Absorption

No information avaliable

Oxaliplatino [Spanish] side effects and Toxicity

No information avaliable

Oxaliplatino [Spanish] Patient Information

Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.

Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.

Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

Oxaliplatino [Spanish] Organisms Affected

Humans and other mammals